- Home
- ABUS vs WDI Comparison
ABUS vs WDI Comparison
Compare ABUS & WDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- WDI
- Stock Information
- Founded
- ABUS 2005
- WDI 2021
- Country
- ABUS United States
- WDI United States
- Employees
- ABUS N/A
- WDI N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- WDI Trusts Except Educational Religious and Charitable
- Sector
- ABUS Health Care
- WDI Finance
- Exchange
- ABUS Nasdaq
- WDI Nasdaq
- Market Cap
- ABUS 711.2M
- WDI 775.8M
- IPO Year
- ABUS N/A
- WDI N/A
- Fundamental
- Price
- ABUS $4.20
- WDI $15.08
- Analyst Decision
- ABUS Strong Buy
- WDI
- Analyst Count
- ABUS 3
- WDI 0
- Target Price
- ABUS $5.67
- WDI N/A
- AVG Volume (30 Days)
- ABUS 1.0M
- WDI 192.6K
- Earning Date
- ABUS 11-05-2025
- WDI 01-01-0001
- Dividend Yield
- ABUS N/A
- WDI 11.80%
- EPS Growth
- ABUS N/A
- WDI N/A
- EPS
- ABUS N/A
- WDI 1.12
- Revenue
- ABUS $15,416,000.00
- WDI N/A
- Revenue This Year
- ABUS $138.02
- WDI N/A
- Revenue Next Year
- ABUS N/A
- WDI N/A
- P/E Ratio
- ABUS N/A
- WDI $12.82
- Revenue Growth
- ABUS 53.23
- WDI N/A
- 52 Week Low
- ABUS $2.71
- WDI $12.16
- 52 Week High
- ABUS $4.73
- WDI $14.69
- Technical
- Relative Strength Index (RSI)
- ABUS 84.85
- WDI 57.46
- Support Level
- ABUS $3.60
- WDI $14.97
- Resistance Level
- ABUS $4.10
- WDI $15.07
- Average True Range (ATR)
- ABUS 0.17
- WDI 0.09
- MACD
- ABUS 0.06
- WDI -0.00
- Stochastic Oscillator
- ABUS 83.33
- WDI 59.73
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About WDI Western Asset Diversified Income Fund of Beneficial Interest
Western Asset Diversified Income Fund is a newly-organized, diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income.